MAAT INDEX

CLAIM #33085 · Intuitive Surgical Inc (ISRG) · 2023Q1 earnings call · Apr 18, 2023 · due Dec 31, 2023

Yes. I would say roughly, depending on where you are in the range, Q2 and Q3 operating expenses should be roughly similar to Q1, and you start to see a less of effect just from the payroll tax reset in Q2 and Q3 as those max out, and you should see Q4 seasonally higher.

Jamie Samath · CFO

PENDING
graded after results covering Dec 31, 2023 are reported

In context

hey've accumulated with the experience of their programs. Hard to answer your question directly in terms of what would the capital environment be if it were in, let's say, normalized times. For us, I think we're focused on this period on offering customers flexibility in how they acquire capital, meeting them with their financial objectives and serving their objectives in expanding their robotic programs. Robert Marcus: Great. And maybe just a quick follow-up. Jamie, as we think about your OpEx progression through the year, it came in a bit higher than the Street had in first quarter. How should we think about that flowing through the rest of the year? And was there anything or any kind of big quarters that we should be thinking about in our progression through the year? Jamie Samath: Yes. I would say roughly, depending on where you are in the range, Q2 and Q3 operating expenses should be roughly similar to Q1, and you start to see a less of effect just from the payroll tax reset in Q2 and Q3 as those max out, and you should see Q4 seasonally higher. Operator: Next, we'll go to Larry Biegelsen with Wells Fargo. Larry Biegelsen: Gary, you've talked about competition potentially lengthening the capital placement cycle. But my question is, if there's an effort by a competitor to discount I&A by 30% or so, how would this impact your procedures? And secondly, Gary, why is this the right time to increase price in I&A? And I had one follow-up. Gary Guthart: Yes. On the first question of what's real pricing out there, there's a few competitors out there, a couple are trumpeting marketing claims about how much they're going to reduce I&A pricing. When we see them in tenders, when we actually see what's written down, we don't see the marketing claim. So I don't know that that's been realized yet or if it's something they want to do in the fu

Verify independently

SEC filings for ISRG · Claim quote is verbatim from the 2023Q1 earnings call.